Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015

Print RSS Feed

Lonza, BioWa License Cell Line Technology to MedImmune

By Kristin Brooks

Published December 11, 2013
BioWa, Inc. and Lonza have entered an agreement with MedImmune to license the Potelligent CHOK1SV Cell Line Technology for use in multiple proprietary antibodies in MedImmune’s pipeline.
Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent Technology with Lonza’s GS Gene Expression System, which includes Lonza’s host cell line, CHOK1SV. Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.
“We are very pleased to extend our relationship with MedImmune, a global biologics company who has recognized the core value of Potelligent Technology for the development of antibody-dependent cellular cytotoxicity enhanced antibodies,” said Yasunori Yamaguchi Ph.D., president and chief executive officer of BioWa.
“It is a pleasure for us to enter to this agreement with MedImmune and BioWa,” said Karen Fallen, vice president and head of licensing, Lonza Custom Development Services. “The combination of Lonza’s well-known GS System coupled with Potelligent CHOK1SV Cell Line provides our customers with a significant advantage in expression technology.”
“The combination of the technologies from BioWa and Lonza will help enhance our ability to produce high quantity potent antibodies for preclinical and clinical development programs, which is a key driver in making better medicines to treat patients,” said Herren Wu, vice president, R&D, global head of Antibody Discovery and Protein Engineering, MedImmune.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On